Novartis

177 results found.

Liver Transplant Clinical Trial using Minimisation of TAC; TAC + MMF + corticosteroids

Novartis - Recruiting 18 years to 70 years.
- A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. The REDUCE Study..
Minimisation of TAC; TAC + MMF + corticosteroids

Locally Advanced or Metastatic BRAF Mutant Melanoma Clinical Trial using LEE011; LGX818

Novartis - Recruiting 18 years or older.
- A Phase Ib/II, Mulicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma..
LEE011; LGX818

Breast Cancer Clinical Trial using LEE011; Letrozole; BYL719

Novartis - Recruiting 18 years or older.
- A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer.
LEE011; Letrozole; BYL719

Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia Clinical Trial using midostaurin

Novartis - Recruiting 3 Months to 18 years.
- A Phase I/II, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Twice Daily Oral Midostaurin and to Evaluate the Preliminary Clinical and Pharmacodynamic Response in Pediatric Patients With Relapsed or Refractory Leukemia.
midostaurin

Locally Advanced or Metastatic NRAS Mutant Melanoma Clinical Trial using LEE011 and MEK162

Novartis - Recruiting 18 years or older.
- A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma.
LEE011 and MEK162

Non-Small Cell Lung Cancer Clinical Trial using LDK378; pemetrexed; docetaxel

Novartis - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib.
LDK378; pemetrexed; docetaxel

Melanoma, Breast Neoplasms, Lobular Carcinoma, Triple-negative Br Clinical Trial using LGK974

Novartis - Recruiting 18 years or older.
- A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands.
LGK974

Solid Tumors Clinical Trial using LCL161; Paclitaxel

Novartis - Recruiting 18 years or older.
- A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors.
LCL161; Paclitaxel

Neuroendocrine Tumors Clinical Trial using Pasireotide LAR

Novartis - Recruiting 18 years or older.
- A Phase I, Multi-center, Open-label, Dose Escalation Study of Pasireotide (SOM230) LAR in Patients With Advanced Neuroendocrine Tumors (NETs).
Pasireotide LAR

Chronic Myeloid Leukemia Clinical Trial using Nilotinib

Novartis - Recruiting 18 years or older.
- Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase.
Nilotinib

Transfusional Hemosiderosis Clinical Trial using deferasirox

Novartis - Recruiting 2 years or older.
- International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting.
deferasirox

KRAS Mutated Colorectal Adenocarcinoma, Metastatic Pancreatic Ade Clinical Trial using MEK162 + AMG 479

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors.
MEK162 + AMG 479

Multiple Sclerosis Clinical Trial using AIN457

Novartis - Recruiting 18 years to 55 years.
- A 1-year Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis..
AIN457

Geographic Atrophy, or Age-related Macular Degeneration Clinical Trial using LFG316; Sham

Novartis - Recruiting 55 years to 90 years.
- A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration.
LFG316; Sham

Multiple Sclerosis, or Relapsing-Remitting Clinical Trial using Fingolimod

Novartis - Recruiting 18 years to 65 years.
- A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)- Fine.
Fingolimod

Retinal Vein Occlusion Clinical Trial using RFB002; Dexamethasone

Novartis - Recruiting 18 years or older.
- An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18).
RFB002; Dexamethasone

Hepatitis C Clinical Trial using BZF961; Ritonavir; Placebo

Novartis - Recruiting N/A or older.
- Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients.
BZF961; Ritonavir; Placebo

Choroidal Neovascularization (CNV) Clinical Trial using Ranibizumab; Sham control

Novartis - Recruiting 12 years or older.
- A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to VEGF-driven Choroidal Neovascularization.
Ranibizumab; Sham control

Age-related Macular Degeneration, or Choroidal Neovascularization Clinical Trial using Ranibizumab 0.5mg

Novartis - Recruiting 50 years or older.
- A 12-month, Phase IIIb, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular AMD.
Ranibizumab 0.5mg

Shigellosis Clinical Trial using 1790GAHB vaccine; GAHB-Placebo

Novartis - Recruiting 18 years to 45 years.
- A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults..
1790GAHB vaccine; GAHB-Placebo

Schizophrenia Clinical Trial using Iloperidone; Placebo

Novartis - Recruiting 18 years to 65 years.
- A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension.
Iloperidone; Placebo

Multiple Sclerosis Clinical Trial using Fingolimod; Interferon beta 1b

Novartis - Recruiting 18 years to 50 years.
- A 18-month, Open-label, Rater-blinded, Randomized, Multi-center, Active-controlled, Parallel-group Pilot Study to Assess Efficacy and Safety of Fingolimod in Comparison to Interferon Beta 1b in Treating the Cognitive Symptoms Associated to Relapsing-remitting Multiple Sclerosis and to Assess Possible Relationship of These Effects to Regional Brain Atrophy.
Fingolimod; Interferon beta 1b

Macular Edema, or Central Retinal Vein Occlusion Clinical Trial using Ranibizumab 0.5 mg/0.05 ml, intravitreal injection

Novartis - Recruiting 18 years or older.
- A 24-month, Phase IIIb, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal.
Ranibizumab 0.5 mg/0.05 ml, intravitreal injection

Proliferative Diabetic Retinopathy (PDR) Clinical Trial using Ranibizumab; Laser photocoagulation; Ranibizumab & laser photocoagulation

Novartis - Recruiting 18 years or older.
- Multicenter Randomized Open-label Three-arms Controlled 12 Months Clinical Proof of Concept Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy.
Ranibizumab; Laser photocoagulation; Ranibizumab & laser photocoagulation

Acute Demylelinating Optic Neuritis Clinical Trial using Fingolimod 0.5mg/daily; Placebo

Novartis - Recruiting 18 years to 50 years.
- A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis.
Fingolimod 0.5mg/daily; Placebo

Prevention of the Meningococcal Disease Clinical Trial using rMenB+OMV NZ

Novartis - Recruiting 18 years to 65 years.
- A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive..
rMenB+OMV NZ

Advanced, Metastatic Breast Cancer Clinical Trial using LEE011; Letrozole; Letrozole Placebo

Novartis - Recruiting N/A or older.
- A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease.
LEE011; Letrozole; Letrozole Placebo

Type 2 Diabetes Mellitus Clinical Trial using LAF237 50 mg; Placebo

Novartis - Recruiting 20 years to 74 years.
- A 12-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Equa (Vildagliptin) 50 mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.
LAF237 50 mg; Placebo

Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamo Clinical Trial using Paclitaxel; Buparlisib; Buparlisib Placebo

Novartis - Recruiting 18 years or older.
- Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Paclitaxel; Buparlisib; Buparlisib Placebo

Acute Myeloid Leukemia Clinical Trial using Midostaurin (PKC412); Standard of Care

Novartis - Recruiting 18 years to 60 years.
- A Phase II, Randomized, Comparative Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia.
Midostaurin (PKC412); Standard of Care

Multiple Sclerosis Clinical Trial using Interferon beta-1a i.m. injections; Fingolimod oral capsules; Placebo oral capsule; Placebo i.m. injection

Novartis - Recruiting 10 years to 17 years.
- Two-year, Double-blind, Randomzied, Multicenter, Active-controlled Study to Evaluate Safety and Efficacy of Oral Fingolimod Versus Interferon Beta-1a i.m. in Pediatric Patients With Multiple Sclerosis.
Interferon beta-1a i.m. injections; Fingolimod oral capsules; Placebo oral capsule; Placebo i.m. injection

Severe IgE-mediated Asthma Clinical Trial using Omalizumab; Budesonide; Formoterol

Novartis - Recruiting 6 years to 55 years.
- Multicentric, Open-label, Randomized, Parallel--group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12- Month Period, in Patients With Severe IgE-mediated Asthma Inadequately Controlled With High Doses of Corticosteroids..
Omalizumab; Budesonide; Formoterol

Visual Impairment Due to Choroidal Neovascularization Secondary t Clinical Trial using Ranibizumab 0.5mg; Rranibizumab 0.5 mg; Verteporfin PDT

Novartis - Recruiting 18 years or older.
- A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
Ranibizumab 0.5mg; Rranibizumab 0.5 mg; Verteporfin PDT

Spinal and Bulbar Muscular Atrophy Clinical Trial using BVS857; Placebo

Novartis - Recruiting 18 years or older.
- A Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy(SBMA).
BVS857; Placebo

Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Clinical Trial using RAD001

Novartis - Recruiting 18 years or older.
- A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer.
RAD001

Malaria Clinical Trial using KAF156 400 mg; KAF156 800 mg

Novartis - Recruiting 20 years to 60 years.
- A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection.
KAF156 400 mg; KAF156 800 mg

Polymyositis Clinical Trial using Placebo; BAF312

Novartis - Recruiting 18 years to 75 years.
- A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis.
Placebo; BAF312

Wet Age-related Macular Degeneration Clinical Trial

Novartis - Recruiting 50 years or older.
- A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics.

Breast Cancer Clinical Trial using BKM120 Matching placebo; Fulvestrant; BKM120

Novartis - Recruiting 18 years or older.
- A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
BKM120 Matching placebo; Fulvestrant; BKM120

Castration Resistant Prostate Cancer Clinical Trial using SOM230

Novartis - Recruiting 18 years or older.
- Phase 1 Study to Evaluate Safety, and Preliminary Efficacy of Pasireotide LAR in Castration Resistant Prostate Cancer.
SOM230

Active Dermatomyositis Clinical Trial using BAF312 0.5 mg; BAF312 2 mg; BAF312 10 mg; Placebo to BAF312

Novartis - Recruiting N/A or older.
- A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis..
BAF312 0.5 mg; BAF312 2 mg; BAF312 10 mg; Placebo to BAF312

Severe Pulmonary Arterial Hypertension Clinical Trial using QTI571

Novartis - Recruiting 18 years or older.
- An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment.
QTI571

CML Clinical Trial using AMN107

Novartis - Recruiting 18 years or older.
- A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib.
AMN107

Non-Small Cell Lunch Cancer Clinical Trial using BKM120; placebo; Carboplatin; Paclitaxel

Novartis - Recruiting 18 years or older.
- A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology.
BKM120; placebo; Carboplatin; Paclitaxel

Mechanical Ventilation Clinical Trial using BYM338; Placebo

Novartis - Recruiting N/A or older.
- An Exploratory, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of BYM338 on Muscle in Patients Requiring Prolonged Mechanical Ventilation.
BYM338; Placebo

Solid Tumor and Hematologic Malignancies Clinical Trial using MEK162

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors.
MEK162

Pemphigus Vulgaris Clinical Trial using VAY736; Placebo to VAY736

Novartis - Recruiting 20 years to 70 years.
- A Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus Vulgaris.
VAY736; Placebo to VAY736

Acute Migraine Clinical Trial using Acetaminophen 250 mg and Aspirin 250 mg; Placebo

Novartis - Recruiting 18 years or older.
- A Multi-center, Randomized, Double-blind, Parallel-group, Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of a Combination of Acetaminophen and Aspirin vs Placebo in the Acute Treatment of Migraine.
Acetaminophen 250 mg and Aspirin 250 mg; Placebo

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial using NVA237; Long-acting beta 2-agonist (LABA); Placebo

Novartis - Recruiting 40 years or older.
- A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation.
NVA237; Long-acting beta 2-agonist (LABA); Placebo

Fragile-X Syndrome Clinical Trial

Novartis - Recruiting N/A or older.
- EXPLAIN - FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes.

Tuberous Sclerosis Complex-associated Refractory Seizures Clinical Trial using RAD001; Placebo

Novartis - Recruiting 1 year to 65 years.
- A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures.
RAD001; Placebo

Malignant Rhabdoid Tumors (MRT), Neuroblastoma Clinical Trial using LEE011

Novartis - Recruiting 1 year to 21 years.
- A Phase I, Multi-center, Open-label Study of LEE011 in Patients With Malignant Rhabdoid Tumors and Neuroblastoma.
LEE011

Meningococcal Disease Clinical Trial using Novartis Meningococcal ACWY Conjugate Vaccine

Novartis - Recruiting 2 years to 55 years.
- A Multicenter Post Marketing Surveillance Study to Monitor the Safety of Novartis Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 to 55 Years of Age in the Republic of South Korea..
Novartis Meningococcal ACWY Conjugate Vaccine

Tumor Pathway Activations Inhibited by Dovitinib Clinical Trial using Dovitinib (TKI258)

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET.
Dovitinib (TKI258)

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Delet Clinical Trial using INC280; Buparlisib

Novartis - Recruiting 18 years or older.
- A Phase Ib/II, Multi-center, Open-label Study of Single-agent INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma.
INC280; Buparlisib

Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascula Clinical Trial using ranibizumab

Novartis - Recruiting 18 years or older.
- An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases..
ranibizumab

Invasive Group B Streptococcal Disease Clinical Trial

Novartis - Recruiting N/A to 90 Days.
- Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China: Incidence, Case Fatality Rate and Serotype Distribution.

Influenza Clinical Trial using TIV

Novartis - Recruiting 6 Months to 4 years.
- A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age..
TIV

Part 1 - Healthy Volunteers, or Part 2 - Patients With Hypertensi Clinical Trial using LFF269; Placebo to LFF269

Novartis - Recruiting 18 years to 80 years.
- A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects.
LFF269; Placebo to LFF269

Chronic Myelogenous Leukemia in Chronic Phase Clinical Trial using nilotinib

Novartis - Recruiting 18 years or older.
- A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP).
nilotinib

Fragile X Syndrome Clinical Trial using AFQ056

Novartis - Recruiting 18 years to 46 years.
- An Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome.
AFQ056

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial using QVA149; Tiotropium; placebo

Novartis - Recruiting 40 years or older.
- A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation.
QVA149; Tiotropium; placebo

Metastatic Melanoma and Merkel Cell Carcinoma Clinical Trial using Pasireotide sub-cutaneous formulation

Novartis - Recruiting 18 years or older.
- A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c. in Patients With Metastatic Melanoma or Metastatic Merkel Cell Carcinoma.
Pasireotide sub-cutaneous formulation

Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 Clinical Trial using Everolimus

Novartis - Recruiting 10 years or older.
- A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1).
Everolimus

Osteopenia, or Osteoporosis Clinical Trial using BPS804; Placebo

Novartis - Recruiting 45 years to 85 years.
- A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Postmenopausal Women With Low Bone Mineral Density.
BPS804; Placebo

Hypertension Clinical Trial

Novartis - Recruiting 6 years to 17 years.
- A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1.

Meningococcal Disease Clinical Trial using MenACWY-CRM

Novartis - Recruiting 2 years to 10 years.
- Post-licensure Observational Safety Surveillance Study of Quadrivalent Meningococcal ACWY Conjugate Vaccine MenACWY-CRM (Menveo) Vaccination in Children 2 Through 10 Years of Age.
MenACWY-CRM

Advanced Solid Tumor Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors.
INC280

Multiple Sclerosis Clinical Trial using FTY720

Novartis - Recruiting 18 years or older.
- A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis.
FTY720

Breast Cancer Clinical Trial using Paclitaxel + LCL161; paclitaxel

Novartis - Recruiting 18 years or older.
- A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer.
Paclitaxel + LCL161; paclitaxel

Acute Uncomplicated Falciparum Malaria Clinical Trial using COA566; Artemether-lumefantrine dispersible tablet

Novartis - Recruiting N/A or older.
- An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants <5 kg Body Weight.
COA566; Artemether-lumefantrine dispersible tablet

Remote Patient Monitoring in COPD Patients Clinical Trial using Remote Patient Monitoring; Usual care

Novartis - Recruiting 40 years or older.
- A 52-week Multi-center Randomized Trial to Evaluate Remote Patient Monitoring Using the EXACT Patient-reported Outcome Tool on Reduction of Hospitalizations From Exacerbations in Patients With Chronic Obstructive Pulmonary Disease as Compared to Those Managed by Usual Care.
Remote Patient Monitoring; Usual care

Advanced Solid Tumor Clinical Trial using LDE225; Wafarin; Bupropion

Novartis - Recruiting 18 years or older.
- A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors.
LDE225; Wafarin; Bupropion

Breast Cancer Clinical Trial using BYL719; BKM120; Placebo

Novartis - Recruiting 18 years or older.
- A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer.
BYL719; BKM120; Placebo

Visual Impairment Due to Neovascular AMD Clinical Trial using Ranibizumab; Aflibercept

Novartis - Recruiting 18 years or older.
- A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD).
Ranibizumab; Aflibercept

Type 1 Diabetes Mellitus Clinical Trial using Secukinumab; Placebo

Novartis - Recruiting 8 years to 35 years.
- A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus (T1D).
Secukinumab; Placebo

Multiple Sclerosis Clinical Trial using Fingolimod

Novartis - Recruiting N/A or older.
- The Multi-National Pregnancy Fingolimod Exposure Registry in Multiple Sclerosis (Epidemiological Study Protocol FTY720D2404).
Fingolimod

Solid Tumors Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors.
INC280

Safety and Tolerability of Iloperidone Clinical Trial using iloperidone (oral tablet)

Novartis - Recruiting 12 years to 17 years.
- A Multicenter, Open-label, Sequential Cohort, Dose-escalation, 14-day Study to Explore the Tolerability and Pharmacokinetics of Iloperidone 12 to 24 mg/Day Followed by 26 Weeks of Flexible Dosing (6 to 24 mg/Day) in Adolescent Patients (Aged 12 to 17 Years).
iloperidone (oral tablet)

Multifocal Choroiditis, Panuveitis, or Active Vitritis Clinical Trial using LFG316; Conventional Therapy

Novartis - Recruiting 18 years to 65 years.
- A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Multifocal Choroiditis (MFC).
LFG316; Conventional Therapy

Prostatic Neoplasms Clinical Trial using CFG920

Novartis - Recruiting 18 years or older.
- A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer.
CFG920

PI3K Pathway Activated Tumors Clinical Trial using BKM120

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors.
BKM120

Macular Edema (ME) Clinical Trial using Sham control; Ranibizumab

Novartis - Recruiting 12 years or older.
- A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravtitreal Injections in Patients With Visual Impairment Due to VEGF-driven Macular Edema.
Sham control; Ranibizumab

Early Breast Cancer Clinical Trial using LEE011; Letrozole

Novartis - Recruiting 18 years or older.
- A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer.
LEE011; Letrozole

Sporadic Inclusion Body Myositis Clinical Trial using BYM338/bimagrumab; Placebo

Novartis - Recruiting 36 years to 85 years.
- Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability of i.v. BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility in Sporadic Inclusion Body Myositis Patients.
BYM338/bimagrumab; Placebo

Influenza Virus Clinical Trial using Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV); Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)

Novartis - Recruiting 6 Months to 72 Months.
- A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ò6 to < 72 Months of Age..
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV); Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)

PTCH1 or SMO Activated Solid and Hematologic Tumors Clinical Trial using LDE225

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 or SMO Mutated Tumors.
LDE225

Relapse Remitting Multiple Sclerosis Clinical Trial using VAY736; Placebo

Novartis - Recruiting 18 years to 55 years.
- A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis.
VAY736; Placebo

Medulloblastoma,, Rhabdomyosarcoma,, Neuroblastoma,, Hepatoblasto Clinical Trial using LDE225

Novartis - Recruiting 12 Months to 18 years.
- A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma.
LDE225

Mevalonate Kinase Deficiency Clinical Trial using Canakinumab

Novartis - Recruiting 2 years or older.
- An Open-label, Multicenter, Efficacy and Safety Pilot Study of 6-month Canakinumab Treatment With up to 6-month Follow-up in Patients With Active Hyper-IgD Syndrome (HIDS).
Canakinumab

Pre-eclampsia Clinical Trial using Placebo; RLX030

Novartis - Recruiting 18 years to 40 years.
- An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia.
Placebo; RLX030

Stomach Neoplasms; Esophageal Neoplasms; Metastatic Gastric Cance Clinical Trial using AUY922; BYL719

Novartis - Recruiting 18 years or older.
- A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2.
AUY922; BYL719

Metastatic Breast Cancer HR+, HER2- Clinical Trial using Fulvestrant; BKM120; BKM120 matching placebo

Novartis - Recruiting 18 years or older.
- A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment.
Fulvestrant; BKM120; BKM120 matching placebo

Pigmented Villonodular Synovitis, or PVNS Clinical Trial using MCS110; Placebo

Novartis - Recruiting 18 years or older.
- A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS).
MCS110; Placebo

Colorectal Cancer Clinical Trial using LGX818; Cetuximab; BYL719

Novartis - Recruiting 18 years or older.
- A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer.
LGX818; Cetuximab; BYL719

Thalassemia, Non-transfusion Dependent Thalassemia, Myelodysplast Clinical Trial using Single arm MRI test

Novartis - Recruiting 12 years or older.
- An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study).
Single arm MRI test

Allergic Rhinitis Clinical Trial using QAW039; Montelukast; Placebo

Novartis - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Placebo-controlled Three-period Incomplete Cross Over Study to Compare the Efficacy of QAW039 Alone and in Combination With Montelukast in Patients With Allergic Rhinitis Using an Environmental Exposure Chamber.
QAW039; Montelukast; Placebo

Hematological Malignancies Clinical Trial using KRP203

Novartis - Recruiting 18 years to 65 years.
- A Single-arm, Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KRP203 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Hematological Malignancies.
KRP203

Rheumatoid Arthritis Clinical Trial using Secukinumab (AIN457)

Novartis - Recruiting 18 years or older.
- A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis.
Secukinumab (AIN457)

Neoplasms Clinical Trial using Everolimus

Novartis - Recruiting N/A or older.
- An Open Label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment.
Everolimus

Renal Transplant Clinical Trial using tacrolimus; everolimus

Novartis - Recruiting 18 years to 70 years.
- Multicenter, Open-label, Randomized, 24 Months Follow-up, Two Arm Study to Compare the Efficacy of Everolimus in Improving the Cardiovascular Profile in a Regimen With Mycophenolic Acid vs. a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients..
tacrolimus; everolimus

Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Aut Clinical Trial

Novartis - Recruiting N/A or older.
- An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients.

Hepatocellular Carcinoma Clinical Trial using everolimus; everolimus placebo

Novartis - Recruiting 18 years or older.
- A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitorr) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study.
everolimus; everolimus placebo

Advanced Solid Tumor Clinical Trial using BYL719

Novartis - Recruiting 18 years or older.
- A Study of BYL719 in Adult Patients With Advanced Solid Malignancies.
BYL719

Glioblastoma Clinical Trial using BKM120 + temozolomide; BKM120 +temozolomide with/without radiotherapy

Novartis - Recruiting 18 years or older.
- A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma.
BKM120 + temozolomide; BKM120 +temozolomide with/without radiotherapy

Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic My Clinical Trial using HSC835

Novartis - Recruiting 10 years to 55 years.
- A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies.
HSC835

Castration-resistant Prostate Cancer Clinical Trial using BEZ235; BKM120

Novartis - Recruiting 18 years or older.
- Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer..
BEZ235; BKM120

Hypertension Clinical Trial using LCZ696; Olmesartan; LCZ696 matching placebo; Olmesartan matching placebo; amlodipine; hydrochlorothiazide

Novartis - Recruiting 60 years or older.
- A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension.
LCZ696; Olmesartan; LCZ696 matching placebo; Olmesartan matching placebo; amlodipine; hydrochlorothiazide

Neoplasms Clinical Trial using Everolimus; Sandostatin LAR Depot

Novartis - Recruiting N/A or older.
- An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment.
Everolimus; Sandostatin LAR Depot

Invasive Group B Streptococcus Disease Clinical Trial

Novartis - Recruiting 18 years or older.
- Feasibility Study for Identifying a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days..

Chronic Obstructive Pulmonary Disease Clinical Trial using NVA237; Tiotropium; Placebo to NVA237; Placebo to tiotropium; Salbutamol

Novartis - Recruiting 40 years or older.
- A Randomized, Double-blind, Multicenter, 2-period Single-dose Cross-over Study to Assess the Early Bronchodilation of Glycopyrronium Bromide (44 æg o.d.) Compared to Tiotropium (18 æg. o.d.) in Patients With Moderate to Severe COPD (FAST Study).
NVA237; Tiotropium; Placebo to NVA237; Placebo to tiotropium; Salbutamol

Metastatic Colorectal Cancer Clinical Trial using MEK162; Panitumumab

Novartis - Recruiting 18 years or older.
- A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer.
MEK162; Panitumumab

Recurrent Glioblastoma Clinical Trial using BGJ398

Novartis - Recruiting 18 years or older.
- A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma.
BGJ398

Diffuse Large B-Cell Lymphoma Clinical Trial using AEB071

Novartis - Recruiting 18 years or older.
- An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma.
AEB071

Kidney Transplantation, or GI Symptoms Severity Clinical Trial

Novartis - Recruiting 18 years or older.
- Open, Multi-centre, Non-interventional, Observational Study to Characterize the Impact That GI Complaints Have on Patient-reported Outcomes in Patients Who Have Had a Renal Transplant. Patients Will be Evaluated at Visit 1 and Then Again After 4 (+2) Weeks (Visit 2).

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM Clinical Trial using BYL719+cetuximab; cetuximab

Novartis - Recruiting 18 years or older.
- A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
BYL719+cetuximab; cetuximab

Advanced Solid Tumor, or Lymphomas Clinical Trial using LEE011

Novartis - Recruiting 18 years or older.
- A phase1 Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
LEE011

Leukemia, Myeloid, Ph1-Positive Clinical Trial using Nilotinib

Novartis - Recruiting 18 years or older.
- A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID.
Nilotinib

Patient Diagnosed With OCD, or and Resistant to SSRI Treatment (F Clinical Trial using AFQ056; Placebo

Novartis - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof of Concept Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy.
AFQ056; Placebo

Advanced Solid Tumors,, or Metastatic Solid Tumors Clinical Trial using BGJ398; BYL719

Novartis - Recruiting 18 years or older.
- A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors.
BGJ398; BYL719

Adult Patients With Low- and Int-1-risk Myelodysplastic Syndrome Clinical Trial using Erythropoietin alpha; Deferasirox

Novartis - Recruiting 18 years or older.
- An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With Low- and Int-1-risk Myelodysplastic Syndrome..
Erythropoietin alpha; Deferasirox

Squamous Non-small Cell Lung Cancer Clinical Trial using Buparlisib; Buparlisib matching placebo; Docetaxel

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer.
Buparlisib; Buparlisib matching placebo; Docetaxel

CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma Clinical Trial using AEB071; Everolimus

Novartis - Recruiting 18 years or older.
- An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma.
AEB071; Everolimus

Spondylitis, Ankylosing Clinical Trial using Secukinumab; Placebo secukinumab

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis.
Secukinumab; Placebo secukinumab

Spondylitis, Ankylosing Clinical Trial using Secukinumab

Novartis - Recruiting 18 years or older.
- An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis.
Secukinumab

Liver Transplantation Clinical Trial using Everolimus + reduced tacrolimus; Standard tacrolimus

Novartis - Recruiting 18 years or older.
- A 24 Month, Randomized, Controlled, Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants.
Everolimus + reduced tacrolimus; Standard tacrolimus

Cystic Fibrosis Clinical Trial using Tobramycin Inhalation Powder

Novartis - Recruiting 6 years or older.
- A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis.
Tobramycin Inhalation Powder

Chronic Myeloid Leukemia Clinical Trial using nilotinib

Novartis - Recruiting N/A or older.
- A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on Nilotinib.
nilotinib

Coronary Artery Disease Clinical Trial using Serelaxin; Placebo

Novartis - Recruiting 18 years or older.
- A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Effects of Intravenous Serelaxin Infusion on Micro- and Macrovascular Function in Patients With Coronary Artery Disease.
Serelaxin; Placebo

Cure Rate Clinical Trial using KAE609

Novartis - Recruiting 20 years to 60 years.
- An Open Label, Single Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum Malaria Mono-infection.
KAE609

Rheumatoid Arthritis Clinical Trial using Secukinumab (AIN457)

Novartis - Recruiting 18 years or older.
- A Four Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis.
Secukinumab (AIN457)

Pregnancy, Newborn Health Clinical Trial

Novartis - Recruiting N/A or older.
- A Multicenter, Observational Study to Identify Factors That Influence Access of Pregnant Women and Their Infants to Their Local Healthcare Systems.

Kidney Transplantation, Renal Transplantation Clinical Trial using RAD001; Tacrolimus; Cyclosporin A; Enteric Coated Mycophenolate Sodium (EC-MPS) or Mycophenolate Mofetil (MMF); Corticosteroids

Novartis - Recruiting 18 years or older.
- 12 Month, Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Certicanr Based Regimen Either in Combination With Cyclosporin A or Tacrolimus.
RAD001; Tacrolimus; Cyclosporin A; Enteric Coated Mycophenolate Sodium (EC-MPS) or Mycophenolate Mofetil (MMF); Corticosteroids

HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvan Clinical Trial using BKM120; Trastuzumab; Paclitaxel; Placebo

Novartis - Recruiting 18 years or older.
- NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer.
BKM120; Trastuzumab; Paclitaxel; Placebo

Hepatitis C, Liver Disease Clinical Trial using DEB025 200mg; DEB025 300mg; DEB025 400mg

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment na‹ve Patients.
DEB025 200mg; DEB025 300mg; DEB025 400mg

Anaplastic Lymphoma Kinase (ALK), or Non-small Cell Lung Cancer Clinical Trial using LDK378; AUY922

Novartis - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer.
LDK378; AUY922

Branch Retinal Vein Occlusion Clinical Trial using Ranibizumab 0.5 mg; Sham injection

Novartis - Recruiting N/A or older.
- A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom].
Ranibizumab 0.5 mg; Sham injection

Chronic Heart Failure Clinical Trial using Enalapril monotherapy; Aliskiren monotherapy; Aliskiren / Enalapril combination therapy

Novartis - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV)..
Enalapril monotherapy; Aliskiren monotherapy; Aliskiren / Enalapril combination therapy

Cushing's Disease Clinical Trial using SOM230 LAR 30 mg; SOM230 LAR 10 mg

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease.
SOM230 LAR 30 mg; SOM230 LAR 10 mg

Persistent Asthma Clinical Trial using Formoterol; Fluticasone propionate 100 mcg; Fluticasone propionate 250 mcg; Fluticasone propionate 500 mcg; Placebo

Novartis - Recruiting 12 years or older.
- A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma..
Formoterol; Fluticasone propionate 100 mcg; Fluticasone propionate 250 mcg; Fluticasone propionate 500 mcg; Placebo

Chronic Plaque-type Psoriasis Clinical Trial using CJM112; Secukinumab; Placebo

Novartis - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients.
CJM112; Secukinumab; Placebo

Chronic Obstructive Pulmonary Disease (COPD) With Cachexia Clinical Trial using Placebo; BYM338

Novartis - Recruiting 40 years to 80 years.
- A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia.
Placebo; BYM338

Central Retinal Vein Occlusion Clinical Trial using Sham injection; Ranibizumab 0.5 mg

Novartis - Recruiting N/A or older.
- A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Central Retinal Vein Occlusion (CRVO) [Camellia].
Sham injection; Ranibizumab 0.5 mg

Advanced Solid Tumors Clinical Trial using LEE011

Novartis - Recruiting 18 years or older.
- A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors.
LEE011

Relapsing Remitting Multiple Sclerosis Clinical Trial using Fingolimod (FTY720)

Novartis - Recruiting 18 years to 50 years.
- A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.
Fingolimod (FTY720)

Advanced HER2-positive Breast Cancer or Gastric Cancer Clinical Trial using LJM716; Trastuzumab

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer.
LJM716; Trastuzumab

Non-small Cell Lung Cancer Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment.
INC280

Pancreatic Neuroendocrine Tumors (pNET) Clinical Trial using BEZ235; Everolimus

Novartis - Recruiting 18 years or older.
- Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors.
BEZ235; Everolimus

Acromegaly, Pituitary Gigantism Clinical Trial using SOM230LAR

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism.
SOM230LAR

Relapsing Remitting Multiple Sclerosis Clinical Trial using Fingoliomod; Interferon beta 1a or interferon beta 1b or Glatiramer Acetate

Novartis - Recruiting 18 years to 65 years.
- A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC).
Fingoliomod; Interferon beta 1a or interferon beta 1b or Glatiramer Acetate

Relapsing Remitting Multiple Sclerosis (RRMS) Clinical Trial using longitudinal assessment

Novartis - Recruiting 18 years to 65 years.
- A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenyar.
longitudinal assessment

Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Clinical Trial using TKI258

Novartis - Recruiting 18 years or older.
- A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer.
TKI258

Non-Small Cell Lung Cancer Clinical Trial using LDK378

Novartis - Recruiting 18 years or older.
- A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib na‹ve Adult Patients With ALK-activated Non-small Cell Lung Cancer.
LDK378

Breast Cancer Clinical Trial using Capecitabine; Exemestane; Everolimus

Novartis - Recruiting 18 years or older.
- Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With ER+Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole..
Capecitabine; Exemestane; Everolimus

Non-transfusion Dependent Thalassemia Clinical Trial using ICL670 deferasirox

Novartis - Recruiting 10 years or older.
- An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia.
ICL670 deferasirox

Metastatic Renal Cell Carcinoma Clinical Trial using RAD001

Novartis - Recruiting 18 years or older.
- An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma.
RAD001

Normal Hepatic Function,, or Impaired Hepatic Function Clinical Trial using LDE225

Novartis - Recruiting 18 years to 65 years.
- A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function..
LDE225

Relapsing-remitting Multiple Sclerosis (RRMS) Clinical Trial using fingolimod; copaxone

Novartis - Recruiting 18 years to 65 years.
- A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.
fingolimod; copaxone

Age-related Macular Degeneration; Polypoidal Choroidal Vasculopat Clinical Trial using Ranibizumab; Verteporfin PDT; Sham PDT

Novartis - Recruiting 18 years or older.
- A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular PCV.
Ranibizumab; Verteporfin PDT; Sham PDT

Hypertension, or Chronic Kidney Disease Clinical Trial using Valsartan

Novartis - Recruiting 6 years to 17 years.
- A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease.
Valsartan

Fibrodysplasia Ossificans Progressiva Clinical Trial

Novartis - Recruiting 5 years to 35 years.
- Urine Sample Collection From Patients With Fibrodysplasia Ossificans Progressiva (FOP) for Biomarker Analysis.

Compensated Alcohol-related Cirrhosis and Portal Hypertension Clinical Trial using Terlipressin acetate; Serelaxin (RLX030)

Novartis - Recruiting 18 years to 75 years.
- An Exploratory Study to Investigate the Haemodynamic Effects of Serelaxin (RLX030) in Patients With Compensated Cirrhosis and Portal Hypertension.
Terlipressin acetate; Serelaxin (RLX030)

Secondary Progressive Multiple Sclerosis Clinical Trial using BAF312; Placebo

Novartis - Recruiting 18 years to 60 years.
- A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis..
BAF312; Placebo

All Indications for Glivec/Gleevec and Tasigna Clinical Trial using Tasigna, Gleevec

Novartis - Recruiting 18 years or older.
- A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS).
Tasigna, Gleevec

Chronic Myelogenous Leukemia Clinical Trial using nilotinib; imatinib

Novartis - Recruiting 16 years or older.
- A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib.
nilotinib; imatinib

Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflam Clinical Trial using ACZ885

Novartis - Recruiting N/A to 4 years.
- A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS).
ACZ885

Lung Transplantation Clinical Trial using standard therapy; Everolimus (RAD001) as add-on; RAD001

Novartis - Recruiting 18 years or older.
- A 2-arm, Prospective, Randomized, Controlled, Open-label, 12 Month Phase III Trial to Evaluate the Efficacy of Everolimus in Combination With a Centre Specific Standard Immunosuppressive Regimen Consisting of CNI, MPA and Steroids Versus a Standard Triple Immunosuppressive Regimen in Lung Transplant Recipients.
standard therapy; Everolimus (RAD001) as add-on; RAD001

Breast Cancer Clinical Trial using Paclitaxel; BKM120 matching placebo; BKM120

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation..
Paclitaxel; BKM120 matching placebo; BKM120

Renal Function, or Liver Transplant Clinical Trial using Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.

Novartis - Recruiting 1 Month to 17 years.
- A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients..
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.

Gouty Arthritis Clinical Trial using Canakinumab, ACZ885; Triamcinolone acetonide

Novartis - Recruiting 18 years to 85 years.
- A Randomized, Double-blind, Double-dummy, Active Controlled Study of Canakinumab (ACZ885) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective.
Canakinumab, ACZ885; Triamcinolone acetonide

Moderate to Severe Plaque-type Psoriasis Clinical Trial using Secukinumab (AIN457); Placebo

Novartis - Recruiting 18 years or older.
- A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 2 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab.
Secukinumab (AIN457); Placebo

Chronic Hepatitis B Clinical Trial using Telbivudine 600mg; Tenofovir disoproxil fumarate 300mg

Novartis - Recruiting 18 years or older.
- OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept.
Telbivudine 600mg; Tenofovir disoproxil fumarate 300mg

Cushing's Disease,, Acromegaly,, Neuroendocrine Tumors,, Pituitar Clinical Trial using Pasireotide

Novartis - Recruiting 18 years or older.
- An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment.
Pasireotide

Ankylosing Spondylitis Clinical Trial using AIN457; Placebo

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase III Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis.
AIN457; Placebo

Moderate to Severe Palmoplantar Psoriasis Clinical Trial using secukinumab 150 mg; secukinumab 300 mg; Placebo

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 80 Weeks in Subjects With Moderate to Severe Palmoplantar Psoriasis.
secukinumab 150 mg; secukinumab 300 mg; Placebo

Normal Hepatic Function, or Impaired Hepatic Function Clinical Trial using LDK378

Novartis - Recruiting 18 years to 70 years.
- A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDK378 in Subjects With Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
LDK378